We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-7.91%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$118M
AUM Growth
-$15.7M
Cap. Flow
+$577K
Cap. Flow %
0.49%
Top 10 Hldgs %
75.47%
Holding
54
New
–
Increased
13
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
AXGN icon
Axogen
AXGN
+$921K
2
PRTA icon
Prothena Corp
PRTA
+$800K
3
BLUE
bluebird bio
BLUE
+$723K
4
TVTX icon
Travere Therapeutics
TVTX
+$593K
5
TXG icon
10x Genomics
TXG
+$468K

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$1.05M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$984K
3
UTHR icon
United Therapeutics
UTHR
+$921K
4
BMY icon
Bristol-Myers Squibb
BMY
+$753K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$737K

Sector Composition

Rank Sector Weight
1 Healthcare 94.79%
2 Energy 5.2%
3 Consumer Staples 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
26
Karyopharm Therapeutics
KPTI
$169M
$766K 0.65%
38,122
+18,700
+96% +$420K
CYTK icon
27
Cytokinetics
CYTK
$10.7B
$737K 0.63%
25,000
– –
TVTX icon
28
Travere Therapeutics
TVTX
$5.16B
$733K 0.62%
82,000
+42,000
+105% +$593K
DCGO icon
29
DocGo
DCGO
$66.2M
$693K 0.59%
130,000
+20,000
+18% +$162K
APLS
30
DELISTED
Apellis Pharmaceuticals
APLS
$685K 0.58%
18,000
+6,000
+50% +$264K
PTGX icon
31
Protagonist Therapeutics
PTGX
$8.64B
$634K 0.54%
38,000
– –
SILK
32
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$619K 0.53%
41,294
+21,294
+106% +$443K
PGNY icon
33
Progyny
PGNY
$2.49B
$612K 0.52%
18,000
+9,000
+100% +$340K
KNSA icon
34
Kiniksa Pharmaceuticals
KNSA
$4.81B
$521K 0.44%
30,000
– –
KALV
35
DELISTED
KalVista Pharmaceuticals
KALV
$385K 0.33%
40,000
– –
HALO icon
36
Halozyme
HALO
$9.14B
$382K 0.32%
10,000
– –
XENE icon
37
Xenon Pharmaceuticals
XENE
$6.38B
$342K 0.29%
10,000
– –
FOLD
38
DELISTED
Amicus Therapeutics
FOLD
$340K 0.29%
28,000
– –
STOK icon
39
Stoke Therapeutics
STOK
$1.72B
$335K 0.28%
85,000
– –
SRPT icon
40
Sarepta Therapeutics
SRPT
$1.78B
$303K 0.26%
2,500
– –
ARVN icon
41
Arvinas
ARVN
$517M
$295K 0.25%
15,000
– –
XNCR icon
42
Xencor
XNCR
$1.39B
$248K 0.21%
12,300
– –
TSVT
43
DELISTED
2seventy bio
TSVT
$235K 0.2%
59,833
– –
CGEM icon
44
Cullinan Oncology
CGEM
$1.08B
$227K 0.19%
25,114
– –
KROS icon
45
Keros Therapeutics
KROS
$210M
$223K 0.19%
7,000
– –
GOSS icon
46
Gossamer Bio
GOSS
$68.9M
$174K 0.15%
209,088
+110,000
+111% +$127K
GTHX
47
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$173K 0.15%
120,000
+80,000
+200% +$155K
IFRX icon
48
InflaRx
IFRX
$268M
$149K 0.13%
50,000
– –
BCRX icon
49
BioCryst Pharmaceuticals
BCRX
$2.32B
$142K 0.12%
20,000
– –
NKTR icon
50
Nektar Therapeutics
NKTR
$2.19B
$16.7K 0.01%
1,867
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Birchview Capital held 54 positions worth $118M, down 12% from $133M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Birchview Capital's Q3 2023 filing shows 13 increased, 4 reduced and 3 closed positions. The largest sale was Soleno Therapeutics, an estimated $1.05M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital added most to Axogen in Q3 2023, an estimated $921K increase.
  • Birchview Capital's biggest Q3 2023 reduction was United Therapeutics, cutting an estimated $921K.
  • Birchview Capital fully exited Soleno Therapeutics in Q3 2023, selling an estimated $1.05M.
  • Birchview Capital's ten largest holdings make up 75% of its $118M portfolio in Q3 2023.
  • Birchview Capital opened 0 new positions and closed 3 in Q3 2023.
  • Birchview Capital's portfolio value fell 12% quarter-over-quarter to $118M.

Based on Birchview Capital's 13F filing for Q3 2023, filed 14 Nov 2023.